AUTL Stock Overview
A clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Autolus Therapeutics plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.75 |
52 Week High | US$7.45 |
52 Week Low | US$2.01 |
Beta | 2.11 |
11 Month Change | -16.85% |
3 Month Change | -14.58% |
1 Year Change | 27.55% |
33 Year Change | -30.94% |
5 Year Change | -64.66% |
Change since IPO | -85.00% |
Recent News & Updates
Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Aug 15Autolus Therapeutics: Major Inflection Point On The Horizon
Jul 31Recent updates
Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Aug 15Autolus Therapeutics: Major Inflection Point On The Horizon
Jul 31Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
May 14We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely
Nov 06Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
Jun 26We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth
Mar 09Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?
Dec 12Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy
Oct 12Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching
Aug 17Autolus Therapeutics Q2 2022 Earnings Preview
Aug 03Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
Apr 19We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully
Dec 15Autolus: Developing Better CAR-T In Refractory ALL
Jul 20Shareholder Returns
AUTL | US Biotechs | US Market | |
---|---|---|---|
7D | 3.0% | 3.8% | 4.5% |
1Y | 27.6% | 12.6% | 21.7% |
Return vs Industry: AUTL exceeded the US Biotechs industry which returned 12.6% over the past year.
Return vs Market: AUTL exceeded the US Market which returned 21.7% over the past year.
Price Volatility
AUTL volatility | |
---|---|
AUTL Average Weekly Movement | 9.5% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AUTL's share price has been volatile over the past 3 months.
Volatility Over Time: AUTL's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 467 | Chris Itin | www.autolus.com |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma.
Autolus Therapeutics plc Fundamentals Summary
AUTL fundamental statistics | |
---|---|
Market cap | US$955.28m |
Earnings (TTM) | -US$233.98m |
Revenue (TTM) | US$10.50m |
95.1x
P/S Ratio-4.3x
P/E RatioIs AUTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AUTL income statement (TTM) | |
---|---|
Revenue | US$10.50m |
Cost of Revenue | US$137.14m |
Gross Profit | -US$126.65m |
Other Expenses | US$107.34m |
Earnings | -US$233.98m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.88 |
Gross Margin | -1,206.51% |
Net Profit Margin | -2,229.04% |
Debt/Equity Ratio | 45.2% |
How did AUTL perform over the long term?
See historical performance and comparison